Vincent K. Petrella
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
GRC Highlighted as Dividend Champion, Recognized for Competitive Advantages. Gorman-Rupp appeared in recent dividend-focused listings as a Dividend Champion, a distinction given to companies with lengthy records of consecutive dividend increases. Separately, the pump and manufacturing company was featured among profitable stocks noted for their competitive advantages in their respective industries. The stock is currently trading near a support level around $78, with an average analyst price target of roughly $81.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
AIT Q4 2026 Earnings Call Transcript Released. Applied Industrial Technologies released the transcript for its Q4 2026 earnings call, providing detailed insights into recent performance. This follows a period where the stock has shown strength relative to some industrial peers. The release offers investors a direct look at management's commentary on factory order trends and operational updates.
Transaction History
| SHC | ▲ Buy | Grant | 14,970 | $0 | 5/22/2026 | View on chart |
| GRC | ▲ Buy | Grant | 1,344 | $0 | 4/24/2026 | View on chart |
| AIT | ▲ Buy | Grant | 572 | $0 | 1/20/2026 | View on chart |
| SHC | ▲ Buy | Grant | 19,132 | $0 | 5/22/2025 | View on chart |
| GRC | ▲ Buy | Grant | 2,553 | $0 | 4/25/2025 | View on chart |
| AIT | ▲ Buy | Grant | 562 | $0 | 1/23/2025 | View on chart |
| SHC | ▲ Buy | Grant | 20,089 | $0 | 5/24/2024 | View on chart |
| GRC | ▲ Buy | Grant | 2,759 | $0 | 5/8/2024 | View on chart |
| AIT | ▲ Buy | Grant | 850 | $0 | 1/23/2024 | View on chart |
| GRC | ▼ Sell | Other | 2,250 | $0 | 7/3/2023 | View on chart |
| SHC | ▲ Buy | Grant | 15,712 | $0 | 5/26/2023 | View on chart |
| AIT | ▲ Buy | Grant | 1,044 | $0 | 1/24/2023 | View on chart |
| AIT | ▲ Buy | Option Exercise | 3,114 | $127K | 8/18/2022 | View on chart |
| AIT | ▼ Sell | Open Market | 1,000 | $114K | 8/18/2022 | View on chart |
| AIT | ▼ Sell | Open Market | 2,114 | $243K | 8/18/2022 | View on chart |
| GRC | ▼ Sell | Other | 2,250 | $0 | 7/1/2022 | View on chart |
| SHC | ▲ Buy | Grant | 10,643 | $0 | 5/27/2022 | View on chart |
| AIT | ▲ Buy | Option Exercise | 2,290 | $107K | 5/4/2022 | View on chart |
| AIT | ▼ Sell | Open Market | 490 | $53K | 5/4/2022 | View on chart |
| AIT | ▼ Sell | Open Market | 1,800 | $195K | 5/4/2022 | View on chart |
| AIT | ▲ Buy | Grant | 1,268 | $0 | 1/25/2022 | View on chart |
| AIT | ▲ Buy | Option Exercise | 2,641 | $116K | 11/16/2021 | View on chart |
| AIT | ▼ Sell | Open Market | 2,641 | $279K | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17
JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17. JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.